Navigation Links
Luminex Corporation Third Quarter Earnings Release Scheduled for November 1, 2011

AUSTIN, Texas, Oct. 11, 2011 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the third quarter of 2011 on Tuesday, November 1, 2011.  A press release announcing the results is scheduled for release after the close of trading.


Management will hold a conference call to discuss the operating highlights and financial results for the third quarter ended September 30, 2011, at 5:00 p.m. Eastern time on November 1, 2011.

The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at  Simply log on to the website, go to the About Us section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software.  If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

The use of pop-up blocking software may impair your ability to view webcasts.  If you use this software, press and hold the CTRL key when you click on the Register button.  Please contact your IT group if you are unable to override this feature.  Unauthorized recording or downloading of this event is not permitted.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP technology can be obtained at

Statements made in this release that express Luminex Corporation's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Luminex Corporate Contact:

Harriss T. Currie
Chief Financial Officer and Vice President, Finance

Luminex Investor Relations Contact:

Matthew D. Scalo
Sr. Director of Investor Relations

SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna
2. Luminex Corporation to Present at Upcoming Investment Conferences In September
3. Luminex Corporation Reports Second Quarter 2011 Results
4. Luminex Corporation Receives U.S. FDA Clearance for New, Front Line Respiratory Viral Panel Test
5. Luminex Corporation Second Quarter Earnings Release Scheduled for August 8, 2011
6. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
7. Luminex Corporation Named Most Innovative Company of the Year and Receives Business Innovation of the Year Award for MAGPIX® System
8. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
9. Luminex and Life Technologies Sign Agreement for Global Distribution of the Award-Winning MAGPIX® Multiplexing Instrument
10. Luminex Corporation to Present at Jefferies 2011 Global Healthcare Conference
11. Luminex Corporation Reports First Quarter 2011 Results
Post Your Comments:
(Date:10/13/2015)... , Oct. 13, 2015  Yesterday Congresswoman ... Vaccines Holly Springs manufacturing site located in ... the facility has produced Flucelvax ® (Influenza Vaccine) using ... potential for faster start-up and is not reliant on ... Limited acquired the influenza vaccines business of Novartis AG ...
(Date:10/12/2015)... 13, 2015 the United States ... a non-clinical capacity. --> the United States ... a non-clinical capacity. --> The University of Texas MD ... the first high field (1.5 Tesla) MRI-guided linear accelerator in ... system will be operating in a non-clinical capacity. Royal ...
(Date:10/12/2015)... , Oct. 12, 2015  Former White House Spokesman, and ... for the House Narcotics Committee, Robert Weiner , and ... Policy." The two emphasize that this is now a potential ... to Jeb Bush , Carly Fiorina to ... the newest federal statistics, which they call "a shocker: 23 ...
Breaking Medicine Technology:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... workflow solutions, announced today their sponsorship of the Microsoft Dynamics AXUG, GPUG and ... AXUG Summit, GPUG Summit and NAVUG Summit are independent user conferences designed and ...
(Date:10/13/2015)... ... October 13, 2015 , ... In an age where ... were 36 percent lower per square foot than in 2009. The Williamsport Regional Medical ... heating and cooling has decreased by eight percent. , According to Facilities Management ...
(Date:10/13/2015)... ... October 13, 2015 , ... e-con Systems Inc., a leading embedded ... See3CAM_CU40, the industry’s first RGB-IR pixel format camera with a USB 3.0 interface ... e-con’s See3CAM family of UVC USB 3.0 cameras, is based on the 1/3-inch OV4682 ...
(Date:10/13/2015)... Los Angeles, CA (PRWEB) , ... October 13, ... ... has published an in-depth review of Anik Singal's newly launched "Publish Academy" ... scaling a digital publishing business opened for enrollment today, and marketers around the ...
(Date:10/13/2015)... , ... October 13, 2015 ... ... Omega-3, a first-of-its kind product that targets the unique health needs of ... of the American Pregnancy Association ( ), utilizes Nordic Naturals’ exclusive, ...
Breaking Medicine News(10 mins):